| Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial HJ Eisen, J Kobashigawa, RC Starling, DF Pauly, A Kfoury, H Ross, ... American Journal of Transplantation 13 (5), 1203-1216, 2013 | 240 | 2013 |
| Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study F Saliba, P De Simone, F Nevens, L De Carlis, HJ Metselaar, ... American journal of transplantation 13 (7), 1734-1745, 2013 | 197 | 2013 |
| Everolimus plus early tacrolimus minimization: a phase III, randomized, open‐label, multicentre trial in renal transplantation RM Langer, R Hene, S Vitko, M Christiaans, H Tedesco‐Silva Jr, ... Transplant International 25 (5), 592-602, 2012 | 150 | 2012 |
| Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial JA Kobashigawa, DF Pauly, RC Starling, H Eisen, H Ross, SS Wang, ... JACC: Heart Failure 1 (5), 389-399, 2013 | 137 | 2013 |
| Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: follow-up results from a randomized, multicenter study L Fischer, F Saliba, GM Kaiser, L De Carlis, HJ Metselaar, P De Simone, ... Transplantation 99 (7), 1455-1462, 2015 | 132 | 2015 |
| Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation J Kobashigawa, H Ross, C Bara, JF Delgado, T Dengler, HB Lehmkuhl, ... Transplant Infectious Disease 15 (2), 150-162, 2013 | 81 | 2013 |
| The stratified win ratio G Dong, J Qiu, D Wang, M Vandemeulebroecke Journal of biopharmaceutical statistics 28 (4), 778-796, 2018 | 64 | 2018 |
| The win ratio: on interpretation and handling of ties G Dong, DC Hoaglin, J Qiu, RA Matsouaka, YW Chang, J Wang, ... Statistics in Biopharmaceutical Research, 2020 | 59 | 2020 |
| A generalized analytic solution to the win ratio to analyze a composite endpoint considering the clinical importance order among components G Dong, D Li, S Ballerstedt, M Vandemeulebroecke Pharmaceutical statistics 15 (5), 430-437, 2016 | 58 | 2016 |
| The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring G Dong, L Mao, B Huang, M Gamalo-Siebers, J Wang, GL Yu, ... Journal of biopharmaceutical statistics 30 (5), 882-899, 2020 | 48 | 2020 |
| Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors FG Villamil, AC Gadano, F Zingale, R Perez, O Gil, S Yantorno, R Mastai, ... Liver International 34 (10), 1513-1521, 2014 | 31 | 2014 |
| TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation J Pascual, TR Srinivas, S Chadban, F Citterio, F Oppenheimer, ... Open Access Journal of Clinical Trials, 45-54, 2014 | 31 | 2014 |
| The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazards G Dong, B Huang, YW Chang, Y Seifu, J Song, DC Hoaglin Pharmaceutical statistics 19 (3), 168-177, 2020 | 26 | 2020 |
| Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time‐to‐event outcomes G Dong, B Huang, J Verbeeck, Y Cui, J Song, M Gamalo‐Siebers, ... Pharmaceutical Statistics 22 (1), 20-33, 2023 | 25 | 2023 |
| Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation A Zuckermann, JM Arizon, G Dong, HJ Eisen, J Kobashigawa, ... Transplantation 92 (5), 594-600, 2011 | 25 | 2011 |
| Efficacy and Safety of Low‐Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial A Zuckermann, SS Wang, H Ross, M Frigerio, HJ Eisen, C Bara, D Hoefer, ... Journal of transplantation 2011 (1), 535983, 2011 | 25 | 2011 |
| Adjusting win statistics for dependent censoring G Dong, B Huang, D Wang, J Verbeeck, J Wang, DC Hoaglin Pharmaceutical Statistics 20 (3), 440-450, 2021 | 24 | 2021 |
| A Bayesian–frequentist two‐stage single‐arm phase II clinical trial design G Dong, WJ Shih, D Moore, H Quan, S Marcella Statistics in Medicine 31 (19), 2055-2067, 2012 | 21 | 2012 |
| Effect of early everolimus-facilitated reduction of tacrolimus on efficacy and renal function in de novo liver transplant recipients: 24-month results for the North American … WC Chapman, RS Brown Jr, KD Chavin, D Sudan, B Koneru, G Junge, ... Transplantation 101 (2), 341-349, 2017 | 12 | 2017 |
| Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus? P De Simone, F Saliba, G Dong, C Escrig, L Fischer Clinical Transplantation 30 (3), 279-288, 2016 | 10 | 2016 |
